Deciphering the Data on Inhaled Insulin: Implications for Pr
Jul 24, 2015 11:06:02 GMT -5
ashiwi and WallStreetIsNotEasy like this
Post by harryx1 on Jul 24, 2015 11:06:02 GMT -5
Deciphering the Data on Inhaled Insulin: Implications for Practice
www.medscape.org/viewarticle/845829
Deciphering the Data on Inhaled Insulin: Implications for Practice CME
Janet McGill, MD; Bruce Bode, MD; Daniel Lorber, MD, CDE
CME Released: 06/26/2015 ; Valid for credit through 06/26/2016
Continue to Activity
This activity is intended for primary care physicians, diabetologists, endocrinologists, and pulmonologists.
The goal of this activity is to review the safety and efficacy data of inhaled insulin and apply it to clinical practice.
Upon completion of this activity, participants will be able to:
- Assess safety and efficacy data of emerging ultra rapid-acting insulin products, focusing on inhaled insulin
- Propose the place in therapy of ultra rapid-acting inhaled insulin
Faculty and Disclosures
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Janet B. McGill, MD
Professor of Medicine, Washington University in St. Louis, St. Louis, Missouri
Disclosure: Janet B. McGill, MD,> has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; MannKind Corporation; Merck & Co., Inc.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: Janssen Pharmaceuticals, Inc.
Received grants for clinical research from: Andromeda Biotech Ltd.; Dexcom, Inc.; Lexicon Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc; Sanofi
Dr McGill does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr McGill does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Bruce W. Bode, MD
Associate Professor of Medicine, Emory University School of Medicine; CEO and President, Atlanta Diabetes Associates, Atlanta, Georgia
The opinions expressed are those of Dr Bode and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Bode's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.
Disclosure: Bruce W. Bode, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen Pharmaceuticals, Inc.; Medtronic, Inc.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals, LP; Janssen Pharmaceuticals, Inc.; Medtronic, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi
Received grants for clinical research from: Abbott Laboratories; AstraZeneca Pharmaceuticals, Inc.; Dexcom, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Medtronic, Inc.; Novo Nordisk; Sanofi
Dr Bode does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Bode does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Daniel Lorber, MD, CDE
Clinical Associate Professor of Medicine, Weill Medical College of Cornell University; Associate Director, Lang Research Center, New York Hospital Queens, Flushing, New York
Disclosure: Daniel Lorber, MD, CDE has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk;
Served as a speaker or a member of a speakers bureau for: Novo Nordisk
Owns stock, stock options, or bonds from: Biodel Inc.
Dr Lorber does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Lorber does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Karen Badal, MD, MPH
Scientific Director, Medscape, LLC
Disclosure: Karen Badal, MD, MPH, has disclosed no relevant financial relationships.
Nafeez Zawahir, MD
CME Clinical Director, Medscape, LLC
Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
www.medscape.org/viewarticle/845829
Deciphering the Data on Inhaled Insulin: Implications for Practice CME
Janet McGill, MD; Bruce Bode, MD; Daniel Lorber, MD, CDE
CME Released: 06/26/2015 ; Valid for credit through 06/26/2016
Continue to Activity
This activity is intended for primary care physicians, diabetologists, endocrinologists, and pulmonologists.
The goal of this activity is to review the safety and efficacy data of inhaled insulin and apply it to clinical practice.
Upon completion of this activity, participants will be able to:
- Assess safety and efficacy data of emerging ultra rapid-acting insulin products, focusing on inhaled insulin
- Propose the place in therapy of ultra rapid-acting inhaled insulin
Faculty and Disclosures
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Janet B. McGill, MD
Professor of Medicine, Washington University in St. Louis, St. Louis, Missouri
Disclosure: Janet B. McGill, MD,> has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; MannKind Corporation; Merck & Co., Inc.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: Janssen Pharmaceuticals, Inc.
Received grants for clinical research from: Andromeda Biotech Ltd.; Dexcom, Inc.; Lexicon Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Pfizer Inc; Sanofi
Dr McGill does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr McGill does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Bruce W. Bode, MD
Associate Professor of Medicine, Emory University School of Medicine; CEO and President, Atlanta Diabetes Associates, Atlanta, Georgia
The opinions expressed are those of Dr Bode and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Bode's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.
Disclosure: Bruce W. Bode, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen Pharmaceuticals, Inc.; Medtronic, Inc.; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals, LP; Janssen Pharmaceuticals, Inc.; Medtronic, Inc.; Merck & Co., Inc.; Novo Nordisk; Sanofi
Received grants for clinical research from: Abbott Laboratories; AstraZeneca Pharmaceuticals, Inc.; Dexcom, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Medtronic, Inc.; Novo Nordisk; Sanofi
Dr Bode does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Bode does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Daniel Lorber, MD, CDE
Clinical Associate Professor of Medicine, Weill Medical College of Cornell University; Associate Director, Lang Research Center, New York Hospital Queens, Flushing, New York
Disclosure: Daniel Lorber, MD, CDE has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk;
Served as a speaker or a member of a speakers bureau for: Novo Nordisk
Owns stock, stock options, or bonds from: Biodel Inc.
Dr Lorber does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Lorber does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Karen Badal, MD, MPH
Scientific Director, Medscape, LLC
Disclosure: Karen Badal, MD, MPH, has disclosed no relevant financial relationships.
Nafeez Zawahir, MD
CME Clinical Director, Medscape, LLC
Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
